Company / R&D Expense
Vericel R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$27.6M
FY2025
5-year range
$13.0M / $30.4M
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#193 of 210
Health Care
What the data says
Among 210 Health Care companies, Vericel is in the bottom 8% for r&d expense. R&D Expense has increased for 3 consecutive years, from $13M in FY2022 to $28M in FY2025.
Based on SEC 10-K filings.
$28M in FY2025 with a 5-year CAGR of +15.2%.
Improved from $21M to $28M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +28.4%
- 5-Year CAGR
- +15.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 210This company $27.6M Sector average $644.1M
▼
-95.7% below sector average
Key checks
Key Insights
- Vericel's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +15.2%, indicating consistent growth.
- In FY2025, r&d expense increased 11.2% year-over-year.
- Ranks #193 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $27.6M | +11.2% |
| FY2024 | $24.8M | +17.8% |
| FY2023 | $21.0M | +61.6% |
| FY2022 | $13.0M | -57.2% |
| FY2021 | $30.4M | +123.5% |
| FY2020 | $13.6M | +5.1% |
| FY2019 | $12.9M | -15.4% |
| FY2018 | $15.3M | -19.0% |
| FY2017 | $18.9M | -11.2% |
| FY2016 | $21.3M | +40.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026